|69.09||-1.57||-2.22%||Vol 2.21M||1Y Perf 33.62%|
|Nov 29th, 2023 16:00 DELAYED|
|1.27 1.84%||- -|
|Target Price||101.42||Analyst Rating||Moderate Buy 1.95|
|Potential %||46.79||Finscreener Ranking||★★★★★ 60.43|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★★+ 58.63|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★+ 63.83|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||81.63||Earnings Rating||Strong Buy|
|Market Cap||5.49B||Earnings Date||7th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.98|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.10M|
|Avg. Monthly Volume||3.26M|
|Avg. Quarterly Volume||1.74M|
CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 69.09 per share at the end of the most recent trading day (a -2.22% change compared to the prior day closing price) with a volume of 2.21M shares and market capitalization of 5.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.
The one-year performance of CRISPR Therapeutics AG stock is 33.62%, while year-to-date (YTD) performance is 69.96%. CRSP stock has a five-year performance of 80.25%. Its 52-week range is between 37.55 and 76.19, which gives CRSP stock a 52-week price range ratio of 81.63%
CRISPR Therapeutics AG currently has a PE ratio of -5.40, a price-to-book (PB) ratio of 1.89, a price-to-sale (PS) ratio of 8 499.47, a price to cashflow ratio of 13.10, a PEG ratio of -, a ROA of -26.31%, a ROC of -27.71% and a ROE of -30.48%. The company’s profit margin is 34.07%, its EBITDA margin is -5 186.50%, and its revenue ttm is $430.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from CRISPR Therapeutics AG, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.98 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (1.95), with a target price of $101.42, which is +46.79% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRISPR Therapeutics AG has a Buy technical analysis rating based on Technical Indicators (ADX : 24.26, ATR14 : 4.24, CCI20 : 87.83, Chaikin Money Flow : 0.15, MACD : 6.81, Money Flow Index : 60.52, ROC : 34.78, RSI : 66.70, STOCH (14,3) : 74.31, STOCH RSI : 0.00, UO : 46.81, Williams %R : -25.69), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Brendan Smith (Option Excercise at a value of $0), James R. Kasinger (Option Excercise at a value of $0), Kasinger James (Option Excercise at a value of $0), Phuong Khanh Morrow (Option Excercise at a value of $0), Samarth Kulkarni (Option Excercise at a value of $4 034 803), Samarth Kulkarni (Sold 200 000 shares of value $10 009 203 ), Smith Brendan (Sold 0 shares of value $0 )
Fri, 27 Oct 2023 16:32 GMT Crispr exa-cel AdCom briefing docs a possible best case, says Mizuho- TipRanks. All rights reserved.
Mon, 14 Aug 2023 14:30 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and Galapagos (GLPG)- TipRanks. All rights reserved.
Mon, 14 Aug 2023 08:25 GMT Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.